LFST stock forecast, quote, news & analysis
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy... Show more
Why LifeStance Health (LFST) Stock Is Up +15% in the Last 30 Days
Key Takeaways
- LifeStance Health (LFST) rose roughly 15% over the last 30 days, extending a multi-month advance that has lifted shares well above their mid-2026 lows.
- The rally builds on a strong second-quarter 2026 report, with revenue up 26% and adjusted EBITDA up 94% year over year, alongside raised full-year guidance.
- Over the last three months, the stock has climbed about 37% as the company's turnaround toward sustained profitability and expanding margins gained traction.
- Growth is underpinned by a larger clinician base, rising visit volumes, and faster-growing specialty services such as TMS and Spravato.
- A $100 million share repurchase program and upward analyst price-target revisions have reinforced positive investor sentiment.
- Investors are closely watching the third-quarter 2026 earnings release, which follows management's guidance for revenue of $420 million to $440 million.
- For deeper data, explore LifeStance's Price Targets, Earnings, and Forecast on additional pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are tracking this and other tickers.
LifeStance Health (LFST) Company Overview and Market Position
LifeStance Health Group, Inc. is one of the largest providers of outpatient mental healthcare in the United States. Founded in 2017 and headquartered in Scottsdale, Arizona, the company delivers virtual and in-person care for children, adolescents, and adults through a network of psychiatrists, advanced practice nurses, psychologists, and therapists. LifeStance employs more than 8,500 clinicians across 33 states and over 550 centers.
The company's model combines a national brand and centralized technology platform with local clinical practices, supporting both therapy and psychiatry services. Investors follow LFST because of its scale in a large, structurally under-served behavioral health market, its ability to expand through tuck-in acquisitions and de novo openings, and its progress toward consistent profitability through margin expansion and productivity gains.
LifeStance Health (LFST) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, LFST advanced approximately 15%, moving from a closing price near $12.22 in early October to roughly $14.07 in recent trading. The move was not a straight line: shares pulled back to the mid-$11 range in mid-October before a steady rally carried them to multi-month highs heading into early November.
The broader three-month trend has been even stronger. From a closing level near $10.26 in early August, the stock has risen about 37%, reflecting a sustained re-rating as the company delivered better-than-expected results and raised its outlook. This quarterly advance marks a continuation of the stock's recovery from depressed levels earlier in the year.
What Drove LFST Stock Price in the Last 30 Days
The recent 30-day advance has been driven by a combination of fundamental momentum and investor positioning. The company's second-quarter 2026 results, reported in early August, showed revenue of $435.4 million, up 26% year over year, with adjusted EBITDA surging 94% to $66 million and net income turning positive. Management also raised full-year 2026 guidance to revenue of $1.685 billion to $1.725 billion and adjusted EBITDA of $215 million to $235 million.
These results established a favorable backdrop that continued to support the stock through October. Market sentiment was further underpinned by the company's growing clinician base, rising visit volumes, expansion of higher-margin specialty services, and a $100 million share repurchase program. As the third-quarter 2026 earnings date approached, buying activity accelerated, reflecting expectations that LifeStance would sustain its double-digit revenue growth and margin improvement.
What Drove LFST Stock Performance Over the Last Quarter
Over the last three months, LFST's roughly 37% gain has been shaped by a broader narrative of operational inflection. The company has delivered consecutive quarters of strong revenue growth and margin expansion, moving from modest profitability toward a more consistent earnings profile. Rising revenue per visit, improved payer contracting, and increased clinician productivity have contributed to higher Center Margin and adjusted EBITDA.
Strategic initiatives have reinforced this trend. LifeStance resumed disciplined tuck-in acquisitions to enter new markets, expanded treatment-resistant depression services including TMS and Spravato, and continued deploying AI-enabled and workflow-automation tools to improve scheduling, documentation, and revenue cycle management. Higher analyst price targets and the company's share repurchase authorization added further support to the stock over the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from a broader universe of hundreds of bots that collectively track thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving visitors a focused view of strategies that are currently standing out. These bots vary in trading approach, timeframe, and performance metrics, so traders can compare different styles rather than relying on a single method. For those interested in how automated, data-driven systems are approaching the market, the page offers a practical starting point to explore AI-powered trading tools.
LFST Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most immediate catalyst for LFST is its third-quarter 2026 earnings report, which follows management's revenue guidance of $420 million to $440 million. Investors will assess whether revenue growth, clinician productivity, and margin expansion continue at recent rates, as well as any update to full-year guidance.
Beyond earnings, key factors include the pace of clinician hiring and retention, revenue per visit trends driven by payer negotiations, and the rollout of specialty services such as TMS and Spravato. The company's planned transition to a new electronic health record system in 2027, tuck-in acquisition activity, and broader macroeconomic and regulatory developments in behavioral health could also influence performance. As with any investment, outcomes depend on execution and market conditions, and past performance does not guarantee future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LFST in upward trend: 10-day moving average crossed above 50-day moving average on October 27, 2026
The 10-day moving average for LFST crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LFST as a result. In 64 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for LFST just turned positive on October 22, 2026. Looking at past instances where LFST's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.
LFST moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFST advanced for three days, in 227 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 178 of 246 cases where LFST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for LFST moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 28 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 66 cases where LFST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
LFST broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. LFST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.544) is normal, around the industry mean (204.532). P/E Ratio (98.357) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (3.182) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement